Emergent BioSolutions (NYSE:EBS) Trading 7.2% Higher – Time to Buy?

Emergent BioSolutions Inc. (NYSE:EBS)’s stock price traded up 7.2% during mid-day trading on Wednesday . The stock traded as high as $10.95 and last traded at $10.96. 908,581 shares traded hands during trading, a decline of 7% from the average session volume of 972,512 shares. The stock had previously closed at $10.22.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday. StockNews.com upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Benchmark increased their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Stock Up 6.1 %

The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The firm has a market cap of $587.53 million, a P/E ratio of -2.64 and a beta of 1.60. The stock’s 50-day simple moving average is $9.27 and its 200 day simple moving average is $9.24.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.88. The company had revenue of $293.80 million for the quarter, compared to analysts’ expectations of $328.72 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter in the prior year, the firm earned ($1.44) EPS. As a group, research analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Emergent BioSolutions

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC purchased a new stake in Emergent BioSolutions in the 2nd quarter valued at about $93,000. Stifel Financial Corp purchased a new stake in Emergent BioSolutions in the 3rd quarter valued at about $96,000. Morse Asset Management Inc purchased a new stake in Emergent BioSolutions in the 2nd quarter valued at about $97,000. FORA Capital LLC purchased a new stake in shares of Emergent BioSolutions during the 3rd quarter worth approximately $103,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Emergent BioSolutions during the 3rd quarter worth approximately $141,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.